Cytox appoints new Chairman

Cytox today announced the appointment of new Chairman, Dr Andrew Carr.

Dr Carr has been working closely with Cytox in an advisory capacity and replaces entrepreneurial investor, David Evans, who steps down after 4 years as Chairman.

Dr Richard Pither, CEO of Cytox, commented, “We would like to acknowledge the excellent leadership David Evans has brought to Cytox during his tenure as Chairman. David has worked closely with the Board to identify his replacement and we are pleased to welcome Dr Andrew Carr, who brings a wealth of experience to see us through the next exciting phase of our genetic-based blood test.”

Dr Carr has experience in both large international companies, such as Amersham Biosciences, GE Healthcare and Thermo Fisher Scientific, as well as smaller biotechs – Teraview, deltaDOT and BAC B.V.

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.